The J9282 code for ZUSDURI facilitates billing and reimbursement, improving patient access to bladder cancer treatment. ZUSDURI, approved by the FDA in June 2025, is the first medication for recurrent ...

In this episode, Jeremy Y.C. Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery), joins host Adam Weiner, MD, to discuss en bloc vs standard transurethral resection of bladder tumor in NMIBC. Teoh ...

The Vanquish Water Vapor System and Hugo robotic-assisted surgery system received FDA clearance for prostate cancer and urologic procedures, respectively, demonstrating high effectiveness and safety.

ADAM, a non-hormonal male contraceptive, shows promise with a favorable safety profile and sustained efficacy in early trials. FDA updates testosterone product labels, removing cardiovascular risk ...

Daniel Spratt, MD, discusses how the ArteraAI Prostate Test (Post-RP) could help guide treatment intensification decisions. On December 9, 2025, Artera announced the commercial launch of the ArteraAI ...

FDA approvals in 2025 included Anktiva, mitomycin, and gemcitabine intravesical systems for BCG-unresponsive and low-grade intermediate-risk NMIBC. Real-world data supported the efficacy and safety of ...

"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and ...

Martin B. Richman, MD, MBA, FACS, outlines recent advancements in BPH, with an emphasis on the importance of a patient-focused approach to care.

RCT compares platinum/5-FU, platinum/paclitaxel in high-risk penile cancer ...

Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...

Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...

A new analysis supports return to widespread screening. A reevaluation of the tradeoffs of prostate cancer screening using the most recent data should rewrite the negative narrative associated with ...